Literature DB >> 26225698

Comparison of Perioperative and Oncologic Outcomes with Laparotomy, and Laparoscopic or Robotic Surgery for Women with Endometrial Cancer.

Tarinee Manchana1, Pimpitcha Puangsricharoen, Nakarin Sirisabya, Pongkasem Worasethsin, Apichai Vasuratna, Wichai Termrungruanglert, Damrong Tresukosol.   

Abstract

PURPOSE: To compare perioperative outcomes and oncologic outcomes in endometrial cancer patients treated with laparotomy, and laparoscopic or robotic surgery.
MATERIALS AND METHODS: Endometrial cancer patients who underwent primary surgery from January 2011 to December 2014 were retrospectively reviewed. Perioperative outcomes, including estimated blood loss (EBL), operation time, number of lymph nodes retrieved, and intra and postoperative complications, were reviewed. Recovery time, disease free survival (DFS) and overall survival (OS) were compared.
RESULTS: Of the total of 218 patients, 143 underwent laparotomy, 47 laparoscopy, and 28 robotic surgery. The laparotomy group had the highest EBL (300, 200, 200 ml, p<0.05) while the robotic group had the longest operative time (302 min) as compared with laparoscopy (180 min) and laparotomy (125 min) (p<0.05). Intra and postoperative complications were not different with any of the surgical approaches. No significant difference in number of lymph nodes retrieved was identified. The longest hospital stay was reported in the laparotomy group (four days) but there was no difference between the laparoscopy (three days) and robotic (three days) groups. Recovery was significantly faster in robotic group than laparotomy group (14 and 28 days, p=0.003). No significant difference in DFS and OS at 21 months of median follow up time was observed among the three groups.
CONCLUSIONS: Minimally invasive surgery has more favorable outcomes, including lower blood loss, shorter hospital stay, and faster recovery time than laparotomy. It also has equivalent perioperative complications and short term oncologic outcomes. MIS is feasible as an alternative option to surgery of endometrial cancer.

Entities:  

Mesh:

Year:  2015        PMID: 26225698     DOI: 10.7314/apjcp.2015.16.13.5483

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  6 in total

1.  Peri-operative and survival outcomes analysis of patients with endometrial cancer managed by three surgical approaches: a long-term Bulgarian experience.

Authors:  Slavcho T Tomov; Grigor A Gorchev; Desislava K Kiprova; Aleksandar D Lyubenov; Nadezhda H Hinkova; Vesela D Tomova; Zornitsa V Gorcheva; Sarfraz Ahmad
Journal:  J Robot Surg       Date:  2022-02-10

Review 2.  Robot-assisted surgery versus conventional laparoscopic surgery for endometrial cancer: a systematic review and meta-analysis.

Authors:  Weimin Xie; Dongyan Cao; Jiaxin Yang; Keng Shen; Lin Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2016-05-23       Impact factor: 4.553

3.  The effect of surgical approach on the outcomes and prognosis of high-risk histologic endometrioid carcinomas.

Authors:  Zhihong Han; Zhong Zheng; Kai Tao; Yanping Yu; Jinping Wu; Xiaofei Tian
Journal:  Gland Surg       Date:  2021-01

4.  A Meta-Analysis of Robotic Surgery in Endometrial Cancer: Comparison with Laparoscopy and Laparotomy.

Authors:  Jia Wang; Xiaomao Li; Haotian Wu; Yu Zhang; Fei Wang
Journal:  Dis Markers       Date:  2020-01-21       Impact factor: 3.434

Review 5.  A comparison of operative outcomes between standard and robotic laparoscopic surgery for endometrial cancer: A systematic review and meta-analysis.

Authors:  Thomas Ind; Alex Laios; Matthew Hacking; Marielle Nobbenhuis
Journal:  Int J Med Robot       Date:  2017-08-01       Impact factor: 2.547

6.  Assessment of Dysfunction in the Urinary System as Well as Comfort in the Life of Women during and after Combination Therapy Due to Ovarian and Endometrial Cancer Based on the SWL, II-Q7 and UDI-6 Scales.

Authors:  Marcin Opławski; Magdalena Smoczyńska; Beniamin Oskar Grabarek; Dariusz Boroń
Journal:  J Clin Med       Date:  2021-03-16       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.